About Us

Intellikine is a venture-backed company focused on the development of potent, selective small molecule inhibitors of the PI3K/Akt/mTOR pathway for the treatment of cancer, inflammation and autoimmune disorders.

Our founders, management team, and advisors include experts in research and early development of drugs against this important family of targets. In addition, we work with leading clinical experts in the diseases we intend to evaluate.

Our most advanced compound, INK128, a selective TORC1/2 inhibitor for the treatment of solid tumor malignancies is in early clinical studies. In addition to INK128, we are advancing a strong pipeline of isoform-selective PI3K inhibitors as potential therapies for a variety of life-threatening diseases.

At Intellikine, we are committed to build the industry’s leading pipeline of small molecule drugs against the PI3K/Akt/mTOR pathway and to advance this pipeline as quickly as possible to create drugs that will improve the lives of patients.